ZNTL

Zentalis Pharmaceuticals, Inc.

Regulated industry Physical products Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $2.61
52-Week Range: $1.21 – $6.95
Market Cap: $247.27M
P/E (TTM): —
EPS (TTM): -1.96
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 1.26
PEG Ratio: —
Return on Equity: -66.75%
Return on Assets: -33.15%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 4.82
Debt/Equity: 0.26
Total Debt: $37.69M
Free Cash Flow: $-79.45M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $43.70M

ZNTL Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$67.42M	$0.00
Research & Development	$172.73M	$189.59M	$167.77M	$107.30M
Selling, General & Admin	$54.55M	$64.35M	$87.11M	$37.72M
Operating Expenses	$227.29M	$253.94M	$254.88M	$145.01M
Operating Income	-$227.29M	-$253.94M	-$187.46M	-$145.01M
EBITDA	-$225.86M	-$252.55M	-$186.17M	-$144.27M
Pretax Income	-$221.30M	-$276.89M	-$165.69M	-$136.62M
Income Tax	-$469.00K	-$601.00K	$177.00K	$442.00K
Net Income	-$236.81M	-$292.19M	-$165.84M	-$137.06M
Diluted EPS	-4.48	-4.47	-2.33	-1.91
Diluted Shares	52.86M	65.41M	71.08M	71.87M

ZNTL Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$43.07M	$28.04M	$33.90M	$35.99M
Receivables	$7.04M	$0.00	$5.00M	$0.00
Current Assets	$451.93M	$496.72M	$386.07M	$253.19M
Total Assets	$539.31M	$551.69M	$430.34M	$288.97M
Current Liabilities	$56.65M	$69.37M	$52.73M	$36.56M
Total Debt	$45.17M	$43.15M	$39.58M	$35.70M
Total Liabilities	$105.29M	$114.30M	$93.15M	$72.76M
Retained Earnings	-$596.37M	-$888.56M	-$1.05B	-$1.19B
Shareholders' Equity	$433.80M	$437.28M	$337.19M	$216.20M
Working Capital	$395.29M	$427.35M	$333.34M	$216.63M

ZNTL Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$163.75M	-$207.82M	-$170.86M	-$125.25M
Capital Expenditure	-$2.55M	-$583.00K	-$221.00K	—
Free Cash Flow	-$166.30M	-$208.41M	-$171.08M	-$125.25M
Depreciation & Amortisation	$1.43M	$1.39M	$1.29M	$739.00K
Stock-Based Compensation	$46.84M	$54.82M	$67.27M	$20.72M
Investing Cash Flow	-$114.18M	-$44.46M	$176.56M	$131.62M
Financing Cash Flow	$261.04M	$237.30M	$108.00K	-$4.28M
Share Repurchases	—	$0.00	$0.00	-$9.98M
Net Change in Cash	-$16.89M	-$14.98M	$5.81M	$2.09M

ZNTL Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$27.25M	$27.61M	$22.95M	$29.49M	$28.72M	$35.16M
Selling, General & Admin	$10.58M	$8.45M	$10.78M	$7.91M	$9.14M	$9.23M
Operating Expenses	$37.83M	$36.06M	$33.73M	$37.39M	$37.85M	$44.39M
Operating Income	-$37.83M	-$36.06M	-$33.73M	-$37.39M	-$37.85M	-$44.39M
EBITDA	-$37.56M	-$35.90M	-$33.57M	-$37.24M	-$37.70M	-$44.24M
Pretax Income	-$48.28M	-$26.87M	-$26.69M	-$34.77M	-$35.23M	-$42.15M
Income Tax	$0.00	$0.00	$0.00	$442.00K	$120.00K	$138.00K
Net Income	-$48.28M	-$26.87M	-$26.69M	-$35.22M	-$35.35M	-$42.29M
Diluted EPS	-0.67	-0.37	-0.37	—	-0.50	-0.59
Diluted Shares	71.68M	71.99M	72.14M	—	70.26M	71.33M

ZNTL Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$41.93M	$37.60M	$39.07M	$35.99M	$31.93M	$24.78M
Receivables	$0.00	$0.00	$0.00	$0.00	—	—
Current Assets	$342.88M	$311.60M	$288.30M	$253.19M	$218.10M	$181.28M
Total Assets	$384.02M	$351.71M	$327.25M	$288.97M	$253.07M	$215.33M
Current Liabilities	$49.43M	$39.02M	$37.17M	$36.56M	$35.24M	$37.63M
Total Debt	$38.65M	$37.69M	$36.71M	$35.70M	$34.65M	$33.56M
Total Liabilities	$88.64M	$77.21M	$74.38M	$72.76M	$70.39M	$71.68M
Retained Earnings	-$1.10B	-$1.13B	-$1.16B	-$1.19B	-$1.23B	-$1.27B
Shareholders' Equity	$295.38M	$274.50M	$252.87M	$216.20M	$182.68M	$143.65M
Working Capital	$293.45M	$272.57M	$251.13M	$216.63M	$182.86M	$143.65M

ZNTL Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$32.64M	-$34.71M	-$26.96M	-$30.94M	-$32.96M	-$37.24M
Capital Expenditure	—	—	—	—	-$34.00K	—
Free Cash Flow	-$32.64M	-$34.71M	-$26.96M	-$30.94M	-$32.99M	-$37.24M
Depreciation & Amortisation	$262.00K	$160.00K	$160.00K	$157.00K	$151.00K	$153.00K
Stock-Based Compensation	$6.49M	$6.29M	$4.83M	$3.12M	$3.20M	$3.21M
Investing Cash Flow	$40.48M	$30.38M	$28.32M	$32.45M	$30.01M	$30.02M
Financing Cash Flow	$189.00K	$0.00	$115.00K	-$4.59M	-$1.12M	$65.00K
Net Change in Cash	$8.03M	-$4.33M	$1.47M	-$3.08M	-$4.07M	-$7.15M

Market Snapshot

About

Zentalis Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer treatment. The company targets genetically defined cancers with precision medicine approaches. Zentalis has multiple oncology programs in clinical development.